You just read:

Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride

News provided by

Eli Lilly and Company

Feb 14, 2019, 06:30 ET